Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms FBP00001
- Sponsors Sanofi Pasteur
- 07 Apr 2020 Status changed from recruiting to completed.
- 31 Jan 2020 Planned End Date changed from 1 Mar 2020 to 1 Feb 2020.
- 31 Jan 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Feb 2020.